We are delighted to see M&C Managing Associate Nick Fischer cited in Endpoints News this week discussing the recent announcement from the MHRA about the "new international recognition framework" to replace the existing European Commission Decision Reliance Procedure.
Full details of the article can be found below and a link to Nick's full commentary can be found here.
An intellectual property law firm says that recent guidance from the UK's Medicines and Healthcare products Regulatory Agency hints at the possibility of the agency allowing approvals from other regulators, including possibly the US FDA, to play a role in UK regulatory processes.
Marks & Clerk, based out of London, wrote in a blog post that guidance from the UK's regulatory agency from late January is providing more context into potential international collaboration with other regulators. How that would come about is after the UK's "Reliance Procedure" — a way to ensure patients in Great Britain post-Brexit could still access new medicines — expires.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
